DHR vs NKE: Which Is the Better Buy?
Side-by-side comparison of Danaher Corporation and NIKE, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-06-20.
Danaher Corporation · Healthcare
$177.17
+8.9% upside to fair value
Grade B
High Quality
VS
NIKE, Inc. · Consumer Cyclical
$45.20
+38.7% upside to fair value
Grade B
High Quality
QuantHub Verdict
NKE has more upside to fair value
(+38.7%).
NKE trades at a lower forward P/E
(29.7x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
DHR |
NKE |
| Current Price |
$177.17 |
$45.20 |
| Fair Value Estimate |
$192.90 |
$62.68 |
| Upside to Fair Value |
+8.9%
|
+38.7%
|
| Market Cap |
$125.4B |
$66.8B |
| Forward P/E |
34.1x
|
29.7x
|
| EV / EBITDA |
20.8x
|
19.4x
|
| Price / Sales |
5.1x
|
1.4x
|
| Price / FCF |
23.7x
|
63.8x
|
| Revenue Growth YoY |
+3.7%
|
+0.1%
|
| Gross Margin |
60.7%
|
40.8%
|
| Operating Margin |
21.0%
|
6.0%
|
| Return on Equity |
7.1%
|
16.4%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.22%
|
1.57%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Danaher Corporation operates in the healthcare sector, specializing in medical diagnostics and research tools through three balanced platforms: Biotechnology, Life Sciences, and Diagnostics. The company benefits from a durable competitive moat supported by the Danaher Business System, disciplined capital allocation, and a platform-centric organizational structure. Despite modest revenue growth of…
NIKE, Inc. is the leading global athletic footwear and apparel brand with a strong competitive moat driven by its iconic brand and extensive innovation capabilities. The company is currently facing earnings pressure with a 34.5% decline in earnings in the most recent quarter and a 10% revenue decline in fiscal 2025, reflecting challenges from tariff-related cost pressures, intense competition, an…
Accumulation Zones
| Metric |
DHR |
NKE |
| Zone Low |
$144.68 |
$47.01 |
| Zone High |
$163.97 |
$53.28 |
| In Buy Zone? |
No
|
Yes
|